Genelux (GNLX) Revenue (2022 - 2024)

Genelux's (GNLX) quarterly Revenue came in at $8000.0 in Q1 2024, down 95.29% year-on-year from $170000.0 in Q2 2023, and down 95.29% quarter-over-quarter from $170000.0 in Q1 2023.

Genelux (GNLX) Revenue (2022 - 2024) Analysis & Trends

Genelux's Revenue history runs 3 years deep, the most recent figure standing at $8000.0 for Q1 2024.

  • On a quarterly basis, Revenue fell 95.29% year-over-year to $8000.0 in Q1 2024; TTM through Dec 2024 was $8000.0, a 95.29% decrease from a year earlier, with the FY2025 full-year figure at $8000.0, changed 0.0% from the prior year.
  • Revenue retreated to $8000.0 in Q1 2024 per GNLX's latest filing, from $170000.0 in the prior quarter.
  • Across five years, Revenue topped out at $11.0 million in Q3 2022 and bottomed at -$10.8 million in Q4 2022.
  • The 3-year median for Revenue is $89000.0 (2023), against an average of $87000.0.
  • Biggest YoY gain for Revenue was 95.29% in 2024; the steepest drop was 95.29% in 2024.
  • Year by year, Revenue stood at -$10.8 million in 2022, then surged by 101.57% to $170000.0 in 2023, then plunged by 95.29% to $8000.0 in 2024.
  • Per Business Quant, the three latest GNLX Revenue figures stand at $8000.0 (Q1 2024), $170000.0 (Q1 2023), and -$10.8 million (Q4 2022).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.51 Bn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 2.99 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 3.61 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 1.56 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Genelux 130.69 Mn 130.69 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2024 8,000.00
Mar 31, 2023 170,000.00
Dec 31, 2022 -10.83 Mn
Sep 30, 2022 11.00 Mn